EUVIMEDEUVIMED entdecken
Crossref

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis

Shlomit Kfir-Erenfeld, Shlomo Elias iD, Nathalie Asherie, Hadass Pri Chen, Elena Karger, Miri Assayag, Emilie Bohbot, Rim Elmikawy, Alaa Shaheen, Ahmad Bazbaz, Tal Friedman-Korn, Vered Molho-Pessach und 22 weitere

Arthritis & Rheumatology · 27.05.2026

DOI: 10.1002/art.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 27.05.2026. Verfasst von Shlomit Kfir-Erenfeld und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Isr…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Immix Biopharma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and preliminary efficacy of HBI0101, B cell maturation antigen targeted chimeric antigen receptor T cell therapy, in patients with severe refractory systemic lupus erythematosus or systemic sclerosis.

Methods

We conducted an ongoing phase 1 trial of HBI0101 in six patients with severe systemic lupus erythematosus (n = 3) or systemic sclerosis (n = 3). The median age was 41 years (range: 21–65), the median disease duration was 2.7 years (range: 1.1–20.5), and patients had received a median of 3.5 previous lines of immunomodulatory therapy (range: 2–9). The median follow‐up was six months (range: 6–9).

Results

Grade 3 to 4 neutropenia occurred in two patients and was managed with supportive care. Three patients had hypogammaglobulinemia requiring intravenous immunoglobulin replacement. Cytokine release syndrome occurred in five patients (grade 2 in three and grade 1 in two) and was absent in one patient. No immune effector cell‐associated neurotoxicity syndrome was observed. In systemic lupus erythematosus, the Systemic Lupus Erythematosus Disease Activity Index 2000 decreased to 0 in two patients and to 4 in one patient. In systemic sclerosis, skin involvement improved in all three patients with reductions in modified Rodnan skin score and European Scleroderma Trials and Research activity indices.

Conclusion

HBI0101 demonstrated an acceptable safety profile and early clinical activity in patients with severe refractory systemic lupus erythematosus or systemic sclerosis, supporting further prospective evaluation. image

Autor:innen und Institutionen

  • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Nephrology and Hypertension, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Rheumatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Neurology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Pathology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.

ORCID-Profile: Shlomo Elias, Chamutal Gur

Förderung

  • Immix Biopharma

Zitieren

APA

Kfir-Erenfeld, S., Elias, S., Asherie, N., Chen, H. P., Karger, E., Assayag, M., Bohbot, E., Elmikawy, R., Shaheen, A., Bazbaz, A., Friedman-Korn, T., Molho-Pessach, V., Vaknin, A., Grisariu, S., Avni, B., Zimran, E., Zalcman, N., Shehadeh, A., Ishtay, A., …, & Gur, C. (2026). B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70211

Vancouver

Kfir-Erenfeld S, Elias S, Asherie N, Chen HP, Karger E, Assayag M, et al. B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70211

BibTeX
@article{KfirErenfeld2026,
  author = {Kfir-Erenfeld, Shlomit and Elias, Shlomo and Asherie, Nathalie and Chen, Hadass Pri and Karger, Elena and Assayag, Miri and Bohbot, Emilie and Elmikawy, Rim and Shaheen, Alaa and Bazbaz, Ahmad and Friedman-Korn, Tal and Molho-Pessach, Vered and Vaknin, Ada and Grisariu, Sigal and Avni, Batia and Zimran, Eran and Zalcman, Nomi and Shehadeh, Alaa and Ishtay, Aseel and Dubnikob, Tatyana and Regev, Shelly and Alexander-Shani, Rivka and Schlossberg, Miriam and Herr, Shlomit and Ben-Shahan, Stephanie and Zorde-Khevalevsky, Elina and Krizhevskaya, Marina and Paran, Daphna and Ravkaie, Lior and Cohen, Cyrille J and Peleg, Hagit and Mevorach, Dror and Stepensky, Polina and Gur, Chamutal},
  title = {B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70211}
}
Kostenlos starten →